Ranibizumab for Edema of the Macula in Diabetes: a Phase 2 Study ( The Read-2 Study)

Trial Profile

Ranibizumab for Edema of the Macula in Diabetes: a Phase 2 Study ( The Read-2 Study)

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms READ-2
  • Most Recent Events

    • 01 Mar 2014 Status changed from active, no longer recruiting to completed, according to results published in the Eye.
    • 30 Jan 2009 Planned end date changed from 1 Jan 2009 to 1 Dec 2009, according to clinicaltrials.gov.
    • 30 Jan 2009 The study duration has been extended to 36 months, according to clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top